业界首个DR智能体来了！美的医疗旗下万东医疗全新搭建"底层硬件—核心算法—影像云—临床场 景"四位一体的高端DR全链新生态。依托旗下专注医学影像人工智能的技术创新平台——万里云医疗， 以云端计算和百万级影像数据为底座来锻造多模态诊断大模型，联合美的AI研究院、美的中央研究 院、阿里达摩院三大顶尖技术团队，推出业界首个DR智能体，实现万东医疗在AI医疗领域从扫描到诊 断、从硬件到软件的全链路战略布局。 实现"拍片即报告"，重塑影像工作流 万东DR智能体的核心价值在于对临床工作流的重塑。传统模式下，影像检查与诊断报告生成之间存在 时间差，智能工具碎片化，而万东DR智能体实现了影像全流程的自动化，一键完成智能摆位及拍片、 AI图像质控，以及常见胸部疾病（如：肺结核、肺炎、气胸、骨折等）自动检出，并智能生成完整结 构化诊断报告，完成影像采集到分析诊断的无缝衔接。 从单点识别到关联推理：实现诊断逻辑闭环 在医疗资源分布不均、服务需求持续增长的当下，此类技术不仅大幅提升了诊疗效率与一致性，更为基 层医疗注入了专家级的能力支撑，实质性地推动了优质医疗资源的下沉与标准化建设。这不仅是技术产 品的成功，更是以生态协同推动医疗服 ...

Core Viewpoint - WanDong Medical is expected to report a significant net loss for 2025, transitioning from a profitable state to a phase of pressure on earnings [1][3]. Performance Overview - The company forecasts a net profit attributable to shareholders of between -199 million to -257 million yuan for 2025. - The net profit after deducting non-recurring items is expected to be between -213 million to -271 million yuan. - In contrast, the company achieved a net profit of 157 million yuan in 2024, with a net profit of 142 million yuan after deducting non-recurring items, indicating a clear reversal in performance for 2025 [3]. Reasons for Performance Pressure - The decline in performance for 2025 is attributed to three main factors: 1. The impact of centralized procurement and price adjustments on gross profit margins. The company is participating in centralized procurement for medical equipment, adopting more competitive pricing strategies to increase bid success rates, which compresses product gross margins and affects current profits [4]. 2. Increased R&D investment leading to short-term cost pressures. The company is intensifying R&D in high-end medical imaging equipment, focusing on CT, MR, and DSA products, which results in a temporary drag on profits due to increased R&D expenditures [5]. 3. Rising costs associated with expanding into overseas and high-tier hospital markets. The company is advancing its overseas market layout and enhancing its marketing and organizational investments in domestic high-tier hospitals, leading to increased costs [6]. Industry Perspective - The expected loss for WanDong Medical in 2025 is seen as a typical case of "transitional pressure" in the imaging equipment industry amid centralized procurement and structural upgrades. - High-end imaging equipment is gradually being included in more price-constrained procurement systems, making it difficult for domestic manufacturers to avoid temporary declines in gross margins, even with increased bid volumes. - The shift towards high-end, systematic, and overseas operations inherently requires longer cycles, higher R&D intensity, and heavier organizational investments. - The company has not retreated from its strategic goals but has chosen a path of "exchanging scale for time and investment for technological reserves" in the centralized procurement environment. This strategy may be unfavorable for profits in the short term but is worth observing from a medium to long-term perspective, especially in core areas like CT, MR, and DSA where domestic replacement is deepening [7]. Key Variables for the Future - The future performance will depend on the commercialization pace of high-end imaging products, the efficiency of overseas market order conversions, and the ability to rebalance product structure and gross margins post-centralized procurement [8].

Summary of WanDong Medical Conference Call Company Overview - **Company**: WanDong Medical - **Parent Company**: Midea Group - **Industry**: High-end medical equipment, focusing on CT, MR, and DSA technologies Key Points and Arguments Strategic Shift and Market Positioning - Since joining Midea Group in 2021, WanDong Medical has shifted its strategic focus towards the high-end medical equipment market, particularly in CT, MR, and DSA sectors, aiming to transition from traditional low to mid-end markets to high-end clients [2][5] - The company is actively expanding its overseas market presence, aligning with the "Belt and Road" initiative, which supports its internationalization strategy [2][5] Response to Market Challenges - The centralized procurement policy has provided WanDong Medical with opportunities to enter mainstream public hospital markets, despite facing pressure on gross margins [2][5] - The company is overcoming challenges by offering high cost-performance products and a flexible product matrix, launching new products like the 64-slice 128-layer cardiac CT and high-end 3T MRI [2][5] Internationalization and Collaboration - Midea Group's acquisition of Reiko International aims to enhance international business, with both companies complementing each other in product positioning and market reach [2][7] - Future capital operations may be implemented to avoid competition between WanDong and Reiko, ensuring optimal resource utilization [2][7] Innovation and R&D Focus - WanDong Medical is increasing its R&D investments, particularly in high-end medical imaging equipment, establishing a technology reserve system to enhance future product competitiveness [3][11] - The company is developing innovative products, including a helium-free MRI, which is expected to lead the market trend towards more sustainable technologies [12][18] Financial Performance and Market Strategy - Despite short-term profit pressures due to increased R&D and marketing expenses, the company is focused on long-term growth and value creation for shareholders [4][13] - WanDong Medical anticipates significant market share growth in mid to low-end CT and MRI markets, aiming for a top-three position in its segments by 2025 [15] AI and Smart Technology Integration - The company is investing in AI technologies for smart scanning, imaging, and management, aiming to transform imaging devices into intelligent systems [16][17] - Current projects include the development of smart DR systems and integrated diagnostic solutions for specific conditions like adolescent scoliosis [16][17] Future Outlook - WanDong Medical expects to maintain a strong growth trajectory, with a focus on high-end and innovative products, while expanding its international market share to 40-45% of total revenue by 2026 [15][19] - The company is committed to enhancing its operational efficiency and cost structure to improve overall profitability [11][14] Additional Important Insights - The company is strategically positioning itself to adapt to the ongoing changes in the medical equipment market, particularly with the implementation of centralized procurement policies [9][11] - WanDong Medical's approach to product differentiation and innovation is crucial for maintaining competitiveness against established players in the industry [12][19]

格隆汇2月2日丨万东医疗(600055.SH)公布，截至2026年1月月底，公司通过集中竞价交易方式累计回购 股份1,802,700股，已回购股份占公司总股本的比例为0.2564%，购买的最高价为17.99元/股、最低价为 15.71元/股，已支付的总金额为29,992,822.08元（不含交易费用）。 ...

格隆汇2月2日丨万东医疗(600055.SH)公布，截至2026年1月月底，公司通过集中竞价交易方式累计回购 股份1,802,700股，已回购股份占公司总股本的比例为0.2564%，购买的最高价为17.99元/股、最低价为 15.71元/股，已支付的总金额为29,992,822.08元（不含交易费用）。 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2026-011 2025 年 8 月 22 日，北京万东医疗科技股份有限公司（以下简称"公司"） 召开第十届董事会第十次会议，审议通过《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股 份，用于员工持股计划或股权激励，回购股份金额为人民币 3,000 万元（含） -6,000 万元（含），回购股份价格不超过人民币 25 元/股，实施期限为自公司 第十届董事会第十次会议审议通过本次回购方案之日起 12 个月内。具体内容 详见公司于 2025 年 8 月 23 日在上海证券交易所网站披露的《万东医疗关于 以集中竞价交易方式回购股份方案的公告》（公告编号：临 2025-038）。 二、 回购股份的进展情况 北京万东医疗科技股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/23 | | | | | | --- | --- | --- ...

证券代码：600055 证券简称：万东医疗 公告编号：2026-010 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 2.1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1 亿元,自有资金 1 亿元； 子公司使用自有资金 1.1 亿元 ...

万东医疗公告称，2025年8月22日，公司决定以集中竞价交易方式回购股份，用于员工持股或股权激 励，回购金额3000万元-6000万元，价格不超25元/股，实施期限至2026年8月21日。截至2026年1月底， 公司累计回购180.27万股，占总股本的0.2564%，支付总金额2999.28万元，回购价15.71元/股-17.99元/ 股。2026年1月未实施回购。 ...

与此同时，公司持续加大研发投入，同时积极拓展海外市场并强化国内高等级医院的营销力度，助力公 司向大放、向高端、向海外的战略转型，但也导致净利润承压。 面对行业结构性升级挑战，公司引进专业研发技术人员，深化高端医学影像设备的全面布局，尤其是大 放品类的CT、MR和DSA。公司聚焦核心零部件及高性能设备研发，构建"研究一代、储备一代、开发 一代"的技术储备格局。同时，公司加速海外市场的覆盖和深耕，持续完善海外营销组织架构和职能体 系，通过实施海外驻点扩容、构建地域性服务中心等举措，有助提升医疗可及性。 近日，万东医疗（600055）发布公告称，预计2025年度实现归母净利润约亏损1.99亿元至2.57亿元，预 计扣除非经常性损益后的归母净利润约亏损2.13亿元至2.71亿元。 2025年度，公司为适应市场变化，适时优化了营销策略，通过更具竞争力的价格方案成功中标影像设备 项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 ...

万东医疗发布业绩预告，预计2025年全年归属净利润亏损1.99亿元至2.57亿元。万东医疗发布业绩预 告，预计2025年全年扣非后净利润亏损2.13亿元至2.71亿元。 公司公告汇总 万东医疗2025年年度业绩预告 资金流向 1月30日主力资金净流入27.25万元，占总成交额0.29%；游资资金净流入260.04万元，占总成交额 2.75%；散户资金净流出287.29万元，占总成交额3.04%。 业绩披露要点 业绩预告 截至2026年1月30日收盘，万东医疗(600055)报收于15.94元，上涨0.0%，换手率0.84%，成交量5.92万 手，成交额9449.26万元。 当日关注点 交易信息汇总 北京万东医疗科技股份有限公司预计2025年度实现归属于母公司所有者的净利润为-19,873万元 到-25,683万元，扣除非经常性损益后的净利润为-21,323万元到-27,133万元，与上年同期相比由盈转 亏。主要原因为公司参与医疗设备集中采购，调整价格策略影响毛利率，同时加大研发投入及海外和高 端市场拓展，导致净利润承压。本期业绩预告未经会计师事务所审计。 来自交易信息汇总：1月30日主力资金净流入27.25万 ...